A detailed history of Lindbrook Capital, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 12 shares of JANX stock, worth $576. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12
Previous 10 20.0%
Holding current value
$576
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$35.29 - $50.26 $70 - $100
2 Added 20.0%
12 $0
Q2 2024

Jul 31, 2024

BUY
$35.12 - $64.78 $351 - $647
10 New
10 $0
Q2 2023

Jul 28, 2023

BUY
$11.08 - $15.92 $1,385 - $1,990
125 New
125 $1,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.